Last reviewed · How we verify
Disitamab Vedotin Injection （18 weeks）
Anti-CD6 monoclonal antibody
Anti-CD6 monoclonal antibody Used for Relapsed or refractory diffuse large B-cell lymphoma.
At a glance
| Generic name | Disitamab Vedotin Injection （18 weeks） |
|---|---|
| Also known as | DV,RC48-ADC |
| Sponsor | RemeGen Co., Ltd. |
| Drug class | Monoclonal antibody |
| Target | CD6 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Disitamab vedotin targets CD6, a protein involved in the activation and proliferation of T cells, which play a key role in the immune response.
Approved indications
- Relapsed or refractory diffuse large B-cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer (PHASE2)
- Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disitamab Vedotin Injection （18 weeks） CI brief — competitive landscape report
- Disitamab Vedotin Injection （18 weeks） updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI